Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 78 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

13%

10 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

32 recruiting

Enrollment Performance

Analytics

Phase 2

26(43.3%)

N/A

19(31.7%)

Phase 3

7(11.7%)

Phase 4

3(5.0%)

Phase 1

3(5.0%)

Early Phase 1

2(3.3%)

60Total

Phase 2(26)

N/A(19)

Phase 3(7)

Phase 4(3)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (78)

Showing 20 of 78 trials

NCT05759572Phase 2Active Not Recruiting

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Role: collaborator

NCT05401175Not ApplicableRecruiting

Hematopoietic Stem Cell-containing Autologous Blood Reinfusion for Bone Marrow Protection in Cervical Cancer Patients

Role: lead

NCT05401162Not ApplicableRecruiting

Chemotherapy Supported by Autologous Hematopoietic Stem Cells

Role: lead

NCT04276532Not ApplicableActive Not Recruiting

Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus

Role: collaborator

NCT05780372Phase 3Active Not Recruiting

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

Role: collaborator

NCT06802835Phase 1Recruiting

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Role: collaborator

NCT05524168Phase 2Active Not Recruiting

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT07013461Recruiting

International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer

Role: collaborator

NCT05213884Phase 2Completed

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Role: lead

NCT07543848Phase 2Not Yet Recruiting

A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer

Role: lead

NCT07425795Phase 2Recruiting

Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer

Role: lead

NCT06059261Phase 2Recruiting

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Role: lead

NCT06498154Phase 2Recruiting

Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

Role: collaborator

NCT07248696Not ApplicableActive Not Recruiting

Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial

Role: lead

NCT07248670Phase 3Active Not Recruiting

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

Role: lead

NCT07249957Not ApplicableNot Yet Recruiting

Reducing Radiation Target Volume for Stage IIb Cervical Cancer

Role: lead

NCT07217600Phase 4Recruiting

Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy

Role: lead

NCT04555226Not ApplicableRecruiting

The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)

Role: lead

NCT05147844Phase 2Recruiting

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT05044871Phase 2Completed

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Role: collaborator